Author:
Demirer T,Uysal V A,Aylı M,Genc Y,Ilhan O,Koc H,Daglı M,Arat M,Gunel N,Fen T,Dincer S,Ustael N,Yildiz M,Ustun T,Seyrek E,Ozet G,Muftuoglu O,Akan H
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference42 articles.
1. Sarosy G, Leyland-Jones B, Soochan P et al. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768–1782.
2. Wright JC, Golomb FM, Gumport SL et al. Summary of results with triethylenethiophosphoramide. Ann NY Acad Sci 1958; 68: 937–966.
3. Lemaistre CF, Herqıg GP, Herqıg RH et al. High-dose thiotepa and autologous bone marrow rescue for the treatment of breast cancer. Breast Cancer Res Treat 1987; 10: 89.
4. Maranichi D, Pıana L, Blaise D et al. Phase I–II studies of high-dose alkylating agents in poor risk patients with breast cancer with autologous bone marrow transplant. In: ABMT: Proceedings of the Third International Symposium. Dicke K, Spitzer TR, Jagannath S (eds). University of Texas MD Anderson Hospital: Houston, TX, 1987; 475–480.
5. Corringham R, Gılmore M, Prentice H et al. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 1983; 52: 1783–1787.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献